SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): March 18, 2004
DEPOMED, INC.
(Exact name of registrant as specified in its charter)
|
California |
|
001-13111 |
|
94-3229046 |
|
(State of Incorporation or Organization) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
|
|
1360 O’Brien Drive, Menlo Park, California |
|
94025 |
||
|
(Address of principal executive offices) |
|
(Zip Code) |
||
|
|
|
|
|
|
|
Registrant’s telephone no., including area code: (650) 462-5900 |
||||
|
|
|
|
|
|
|
NOT APPLICABLE |
||||
|
(Former name or former address, if changed since last report) |
||||
Item 5. Other Events and Required FD Disclosure
On March 18, 2004, Depomed, Inc., a California corporation, issued a press release announcing top-line results from the Phase III clinical trial of its Ciprofloxacin GR, an extended release formulation of ciprofloxacin HCl, which is used to treat urinary tract infections
Item 7. Exhibits
|
Exhibits |
|
|
|
99.1 |
|
Depomed, Inc. Press Release issued on March 18, 2004 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
DEPOMED, INC. |
||
|
|
|
||
|
|
|
/s/ John F. Hamilton |
|
|
|
|
John F. Hamilton |
|
|
|
|
Vice President - Finance and |
|
Date: March 18, 2004
EXHIBIT INDEX
|
Exhibit |
|
|
|
99.1 |
|
Depomed, Inc. Press Release issued on March 18, 2004 |